Skip to main
ABT

Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Labs (ABT) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Abbott Laboratories is expected to continue its strong performance driven by its diverse product portfolio and expanding presence in high-growth areas such as diabetes, structural heart, and diagnostics. The company's leading market position, successful commercial strategy, and robust pipeline provide a strong foundation for future growth. Additionally, the company's focus on driving affordability and expanding into emerging markets will contribute to its global dominance.

Bears say

Abbott Laboratories is a diversified healthcare company with a strong international presence, but concerns about organic growth, unfavorable changes in healthcare regulation, pricing, and reimbursement, and potential product safety concerns and product liability are key reasons for its negative outlook. Despite management expressing confidence in the company's ability to grow and its effective capital deployment strategy, the longer-term goal of delivering high-single-digit organic sales growth and double-digit EPS growth may not be achievable in the current macro climate. Additionally, Abbott trades at a premium valuation compared to its large-cap peers, making it vulnerable to any negative developments.

Abbott Labs (ABT) has been analyzed by 18 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abbott Labs (ABT) Forecast

Analysts have given Abbott Labs (ABT) a Buy based on their latest research and market trends.

According to 18 analysts, Abbott Labs (ABT) has a Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $129.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $129.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abbott Labs (ABT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.